This prospective, randomized, double-blind, placebo-controlled study evaluated the efficacy of palifermin to reduce the incidence of severe (grade 3 --4) acute GVHD after myeloablation and allo-SCT. Adults who received allo-SCT for hematologic malignancies received placebo or palifermin 60 mg/kg daily on three consecutive days before conditioning and a single dose of 180 mg/kg after conditioning, but often 1 or 2 days before allo-SCT. Subjects received MTX (plus CYA or tacrolimus) on days 1, 3, 6 and 11. Acute GVHD was evaluated once weekly and oral mucositis was evaluated daily. Subjects were randomly assigned to placebo (n ¼ 78) or palifermin (n ¼ 77). Conditioning included TBI in approximately half of the subjects (48% placebo, 51% palifermin). The primary efficacy end point, subject incidence of grade 3 --4 acute GVHD, was similar between treatment groups (17% placebo, 16% palifermin). Grade 3 --4 oral mucositis (73% placebo, 81% palifermin) and other secondary efficacy end points were similar between treatment groups. The most commonly reported treatment-related adverse events were skin/s.c. events such as rash, pruritus, and erythema. This exploratory study of acute GVHD after myeloablation and allo-SCT did not provide evidence of a treatment effect with this dosing regimen of palifermin.
INTRODUCTION
Allo-SCT is the treatment of choice for a variety of hematological malignancies. 1 Although the use of reduced intensity conditioning regimens has increased, myeloablative regimens continue to be a standard of care for young patients. About 35 --50% of allo-SCT recipients develop grade 2 --4 acute GVHD, with a higher incidence after unrelated donor transplants and mismatched donor transplants compared with HLA-identical sibling donor transplants. 2 Oral mucositis with ulceration (World Health Organization (WHO) grade 2 --4) occurs in approximately 75% of patients receiving myeloablative regimens. 3 Prophylaxis with a MTX-and calcineurin inhibitor-based regimen is effective in reducing GVHD, 4 but worsens mucositis in many patients. 5 Keratinocyte growth factor appears to modulate the endogenous response to epithelial injury. In animal studies, recombinant human Keratinocyte growth factor (palifermin) reduced GVHD and inhibited rejection of allo-SCT. 6 --8 Palifermin was shown to decrease the incidence and duration of severe oral mucositis in patients who received TBI-based conditioning therapy and autologous SCT. 9 The approved dose of palifermin for reduction of severe oral mucositis is 60 mg/kg daily by i.v. bolus injections for 3 days before and 3 days after an myeloablative regimen and SCT.
Prior studies evaluated the efficacy and safety of palifermin to reduce GVHD either with this dose, or with a collapsed 180 mg/kg dose 1 day before the start of the myeloablative regimen and 60 mg/kg daily for at least 3 days after the end of the myeloablative regimen. 10 --13 Because MTX is dosed 1, 3, 6 and 11 days after allo-SCT and the interaction between palifermin and MTX was not known, this study used a regimen of three doses (60 mg/kg daily) prior to the start of myeloablative and one collapsed dose (180 mg/kg) at the end of the myeloablative regimen, often prior to allo-SCT.
The primary aim of this randomized, double-blind, placebocontrolled study was to explore the potential of palifermin to reduce the incidence of severe (grade 3 --4) acute GVHD in patients undergoing allo-SCT from either a related donor or an HLA-matched, unrelated donor.
MATERIALS AND METHODS Subjects
Adults of at least 18 years of age were eligible for the study if they had a hematologic malignancy (including myelodysplastic syndromes) and were scheduled to receive allogeneic marrow or PBPC transplantation after one out of six myeloablative conditioning regimens: CY plus TBI ± etoposide, TBI plus etoposide, melphalan plus TBI 41100 cGy, BU plus CY, BU plus melphalan (fully ablative doses) or fludarabine plus melphalan (fully ablative doses). Subjects were required to have Karnofsky Performance Status X70% and to have either a related donor or an HLA-matched unrelated donor identical at 6/6 HLA-A, -B and -DRB1 loci. For unrelated donors, molecular typing of class I and class II was mandatory.
Key exclusion criteria included the following: other malignancies, prior BM or PBPC transplantation, previous use of palifermin, active infection or oral mucositis, congestive heart failure (NYHA class III or IV), use of a T-cell depleted graft for GVHD prophylaxis, inadequate renal, liver or pulmonary function, pregnancy or breast feeding, refusal to use adequate contraception during the study, or participation in another investigational device or drug trial in the previous 30 days.
Study design
This prospective, stratified, randomized, double-blind, placebo-controlled, multicenter phase II study was conducted between December 2005 and November 2008 at 16 sites in the United States and 4 sites in Australia. The study followed the principles of the Declaration of Helsinki. Written informed consent was obtained for each subject and an institutional review board approved the study at each site.
Subjects were randomly assigned in a 1:1 ratio to receive placebo or palifermin by i.v. bolus injections. The randomization scheme was stratified on TBI use (yes or no), matched donor type (related or unrelated) and source of donor cells (marrow or PBPC).
Day 0 was defined as the day of marrow or PBPC transplantation. The recommended dosing schedule for conditioning regimens was from day À11 to day À2. Palifermin 60 mg/kg daily (or matching placebo) was administered on 3 consecutive days before the start of the conditioning regimen. A single dose of palifermin 180 mg/kg or placebo was administered at least 24 h after the last dose of myeloablative chemotherapy or radiation, at least 96 h after the last 60 mg/kg dose of study medication and at least 24 h before the first post-transplant dose of MTX.
Subjects received MTX for GVHD prophylaxis on days 1, 3 and 6 (planned), and on day 11 (if toxicity allowed) at doses of 15, 10, 10 and 10 mg/m 2 , respectively. A calcineurin inhibitor (cyclosporine or tacrolimus) was administered with MTX and dosed per institutional norms. Filgrastim was not required but could be administered per the standard practice at each institution.
Subjects were evaluated for efficacy once weekly ( ± 3 days) for 8 weeks, and then at days 70, 84 and 100 (±7 days). The severity of acute GVHD was evaluated with the modified Keystone criteria assessment scale, 14 based on physical exam and laboratory serum values. Biopsies of affected organs were obtained when possible. The degree of GVHD in individual organs was scored by at least two qualified assessors at the site who were blinded to study medication assignment. The investigator reviewed any discrepant GVHD scores. Two experts (EKW and MJ) independently reviewed GVHD scoring for each enrolled subject.
Trained assessors at each site used the WHO criteria 15 to assess oral mucositis severity at screening and then once daily during hospitalization, from the first day of the conditioning regimen until the subject was discharged or day 28, whichever was earlier. Thereafter, if the subject had grade 3 --4 oral mucositis, the daily oral mucositis assessments were to continue until oral mucositis returned to grade p2. As few assessors as possible were assigned at each site to keep the assessments consistent.
Adverse events and concomitant medications were recorded at each assessment. For each adverse event, the investigator recorded details such as the severity, seriousness, relationship to study medication and resolution of the event. A blood sample for serum palifermin Ab assays was obtained on day 28. Antibodies against palifermin were assayed by an electrochemiluminescence-based immunoassay; a positive test was followed by a cell-based assay for neutralizing antibodies. Information about the use of the total parenteral nutrition was collected up until engraftment or day 28, whichever occurred first.
Efficacy and safety end points
The primary efficacy end point was the subject incidence of severe (grade 3 --4), acute GVHD. Secondary efficacy end points included the incidence of grade 2 --4 acute GVHD, the incidence of MTX prophylaxis on day 11, the incidence of severe oral mucositis (grade 3 --4), the duration of severe oral mucositis (overall and among subjects with severe oral mucositis), the incidence of parenteral or transdermal opioid analgesic use and the incidence of total parenteral nutrition. The incidence and duration of grade 2 --4 oral mucositis were exploratory efficacy end points. Safety was assessed by the subject incidence of adverse events, Ab formation, neutrophil engraftment (ANC X1.0 Â 10 9 /L for 3 consecutive days or X10.0 Â 10 9 /L for 1 day) and platelet engraftment (X20 Â 10 9 /L) by day 100. Neutrophil and platelet counts were done on a weekly basis to coincide with weekly GVHD assessment. Although participating centers followed institutional criteria of checking counts more frequently prior to engraftment, these data were not captured for purposes of the study. Thus, conventional criteria of neutrophil and platelet engraftment could not be followed during the conduct of the study. Previous studies in both autologous and allogeneic transplant did not report any detrimental impact of palifermin on neutrophil and platelet engraftment. 9 --12 Statistical analysis Efficacy analyses included all randomized subjects. Safety analyses included all randomized subjects who received at least one dose of study medication. The study was designed to provide an estimate of the incidence of severe GVHD in an allogeneic transplant setting and was not powered to provide definitive proof of efficacy. The planned sample size was 200 subjects. Because of slow enrollment, a decision was made by the sponsor in consultation with a data-safety monitoring board to terminate the study at 155 subjects. This still allowed an acceptable level of precision for the estimate of the primary end point in this exploratory study and allowed the results to be available up to 12 months earlier. Estimates of treatment differences between palifermin and placebo were provided with 95% confidence intervals (CIs) for the incidence of severe GVHD and other incidence end points. The Cochran --Mantel --Haenszel weight was used to combine estimates across randomization strata.
RESULTS

Subject disposition
Subject disposition is summarized in Figure 1 . Of the 187 potential subjects screened, 155 subjects met the eligibility criteria and were randomly assigned to receive placebo (n ¼ 78) or palifermin (n ¼ 77). Two of the subjects in the placebo group received a dose of commercial palifermin in error; they were included in the placebo group for efficacy analyses and the palifermin group for safety analyses. A total of 151 subjects received at least one dose of study treatment (75 (96%) placebo, 76 (99%) palifermin), most completed study treatment (69 (88%) placebo, 71 (92%) palifermin) and most completed the study (63 (81%) placebo, 55 (71%) palifermin).
Baseline demographics and treatment characteristics Baseline demographics of study participants and the donor source and type were generally similar between treatment groups ( Table 1 ). The use of study medication and TBI were also similar between treatment groups (Table 2 ). Approximately half of the subjects in each treatment group received TBI (35 (48%) placebo, 40 (51%) palifermin), with a mean ± s.d. of 1269.9 ± 149.5 cGy in the placebo group and 1236.1 ± 222.3 cGy in the palifermin group.
Chemotherapy doses were similar between treatment groups ( Table 2 ). The mean CY doses were similar between the two treatment groups (100.3 ± 28.7 vs 100.4 ± 34.4 mg/kg), but more subjects in the palifermin group received CY (57 (78%) placebo, 64 (82%) palifermin), which was given with either TBI or BU (30 (41%) placebo, 33 (42%) palifermin). Compared with the placebo group, fewer subjects in the palifermin group received fludarabine (10 (14%) placebo, 5 (6%) palifermin). Melphalan and etoposide use was similar between treatment groups.
Of the 151 subjects who received study medication, 11 (7%), 82 (55%), and 51 (33%) received the collapsed dose on days À2, À1 and day 0 (day of transplant), respectively. In all, 5 (3%) subjects did not receive a transplant and 2 (1%) others did not receive the collapsed dose.
Efficacy
The between-group differences for GVHD outcomes are shown in Figure 2 . The subject incidence of the primary efficacy end point, grade 3 --4 acute GVHD, was similar between the placebo and palifermin groups (12 (17%) vs 12 (16%); difference (95% CI): 0.5% (À11.0%, 12.1%)). The subject incidence of the secondary efficacy end point, grade 2 --4 acute GVHD, was lower in the placebo group than in the palifermin group (29 (40%) vs 43 (58%); difference (95% CI): À17.9% (À33.4%, À2.4%)). The proportion of subjects who received the final, optional dose of MTX on day 11 was similar Figure 1 . Subject Disposition. * Two subjects in the placebo group received palifermin in error; they were included in the placebo group for the efficacy analysis and the palifermin group for safety analysis. between the placebo and palifermin groups (56 (72%) vs 60 (78%); difference (95% CI): À6.5% (À19.4%, 6.4%)).
The incidences were similar between the placebo and palifermin groups (Figure 2 ) for severe (grade 3 --4) oral mucositis (57 (73%) vs 62 (81%)), grade 2 --4 oral mucositis (69 (88%) vs 69 (90%)), parenteral or transdermal opioid use (50 (64%) vs 48 (62%)) and total parenteral nutrition (38 (49%) vs 43 (56%)). The duration of oral mucositis was also similar between treatment groups (Table 3) , including both the duration of severe oral mucositis (overall and among those subjects with severe oral mucositis) and the duration of grade 2 --4 oral mucositis.
Safety
Most subjects reported at least one adverse event (72 (99%) placebo, 77 (99%) palifermin). There were no clinically significant differences in the subject incidences of individual adverse events between the treatment groups (Table 4) .
Study drug-related adverse events were reported for 23 (32%) placebo subjects and 31 (40%) palifermin subjects. The most commonly reported adverse events that the investigator considered related to the study treatment are shown in Table 5 .
Adverse events in three subjects (2 (3%) placebo, 1 (1%) palifermin) and disease progression in six subjects (2 (3%) placebo, 4 (5%) palifermin) were reported as reasons for study discontinuation. Deaths were reported for 13 subjects during the study (5 (6%) placebo, 8 (10%) palifermin), and 5 subjects within 100 days after the study (2 (3%) placebo, 3 (3%) palifermin). The investigators did not consider any of these deaths to be related to the study medication.
Documented neutrophil count (ANC X10.0 Â 10 9 /L) occurred in 22 (30%) placebo subjects and 30 (38%) palifermin subjects; the proportion of subjects who achieved a lower ANC target on 3 consecutive days could not be analyzed because ANC values were not collected daily. Platelet engraftment (X20 Â 10 9 /L) occurred in 69 (95%) placebo subjects and 74 (95%) palifermin subjects.
One (1%) palifermin subject had a seropositive result for antipalifermin antibodies during screening, prior to palifermin administration; this subject was retested with negative results Figure 2 . Between-group differences and 95% CIs for efficacy outcomes (primary analysis set). Table 3 . Duration of oral mucositis (primary analysis set)
Severe (Grade 3 --4) oral mucositis All subjects 8.1±6. Grade 2 --4 oral mucositis 12.6 ± 7.7 13.5 ± 8.5 À0.6 (À3.2, 1.9)
a Adjusting for the effects of the stratification factors using the Cochran --Mantel --Haenszel weights. on day 28. Seronegative results were obtained from 65 (89%) placebo subjects and 66 (85%) palifermin subjects. The remaining subjects were not tested for anti-palifermin antibodies.
DISCUSSION
Preclinical studies suggested that palifermin decreased GVHD incidence and lethality without decreasing graft-vs-tumor effect. 6 --8 In patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support, palifermin treatment was associated with significant decreases in the incidence and duration of WHO grade 4 and grade 3 --4 mucositis, along with improvement in patient-reported outcomes, use of opioid analgesics and the total parenteral nutrition. 9, 16 However, most of those studies evaluated the effects of palifermin among patients undergoing autologous SCT after an intensive, fractionated TBI-based conditioning regimen.
In allo-SCT, mucositis is related not only to the preparative regimen but also is compounded by the MTX that is used for GVHD prophylaxis. 5 The exact post-preparative dosing regimen for palifermin in allo-SCT is not as clearly defined by clinical data as is the case for autologous-SCT. Several investigators have studied palifermin in allo-SCT---with the intent of decreasing GVHD and sparing graft-vs-tumor effect---using a post-preparative dose of 60 mg/kg daily for at least 3 days, 10 --13 which is the same postpreparative dose that was used in studies of autologous SCT. 9 Using this dosing regimen, a retrospective study concluded that palifermin decreased the incidence of acute GVHD compared with historical controls and it decreased mucositis, opioid requirements and the total parenteral nutrition. 10 However, another retrospective cohort study showed no effect of palifermin on GVHD in allo-SCT. 11 In a prospective, randomized trial, Blazar et al.
12
investigated various dosing regimens of palifermin in allo-SCT and concluded there were no significant differences in acute GVHD incidence, acute GVHD severity, survival or day 100 relapse rates between the palifermin and placebo groups. Palifermin was associated with reduced incidence and severity of mucositis (measured three times weekly), but only in patients conditioned with fractionated TBI-based regimens. 12 Levine et al. 13 reported on the long-term outcomes of this cohort and found no difference between the palifermin and placebo groups in the incidence of chronic GVHD or relapse risk. As shown in some of the prior trials, 11, 12 there was no positive impact of palifermin on either grade 2 --4 or grade 3 --4 acute GVHD incidence or severity.
Mucositis was monitored stringently in this study, with oncedaily assessments by the trained investigators compared with assessments three times weekly in the prior randomized study. 12 Although the previous studies reported a decrease in mucositis, 10 --12 this study did not show any benefit in mucositis incidence, opioid use or the total parenteral nutrition. The altered, collapsed dose and timing for the post-preparative regimen could have been contributing factors. The approved dosing schedule for palifermin includes three daily 60 mg/kg doses before conditioning and three daily 60 mg/kg doses after transplant. In the current study, subjects received the recommended doses of palifermin prior to conditioning, but a collapsed dosing regimen with a single dose of palifermin 180 mg/kg was used after conditioning. Additionally, the postpreparative dose of palifermin was often administered prior to transplant on day À1 or À2 to try to augment mucositis protection prior to initiating MTX on day 1 for GVHD prophylaxis. Use of the collapsed dose of palifermin as the post-dose, combined with the difference in timing compared with the currently approved dose and schedule of palifermin, may be an important limitation in the extrapolation of these results to the expected effects of the approved dosing schedule for palifermin in this setting.
Grade 2 --4 acute GVHD was reported in a higher proportion of patients receiving palifermin compared with placebo. The exact reason for this is not clear. Palifermin-induced skin rashes tend to occur early after administration of the drug and are transient. Although skin rashes post-transplant could be misdiagnosed as skin GVHD, the timing of the rash immediately after the conditioning regimen and prior to engraftment, the recommendation to pursue a skin biopsy on the study prior to the diagnosis of skin GVHD and blinded assessment by two physicians of weekly assessment of acute GVHD data make this an unlikely cause for the higher incidence of GVHD in the palifermin group. Long-term follow-up of the present study is ongoing at 6 months and at 1, 2, 3, 4 and 5 years to evaluate chronic GVHD, disease status and secondary malignancies.
Neutrophil engraftment rates were similar between treatment groups. Neutrophil engraftment was defined as ANC of X1.0 Â 10 9 /L for 3 consecutive days or ANC of X10.0 Â 10 9 /L for 1 day, whichever was sooner. The ANC target of X1.0 Â 10 9 /L for 3 consecutive days could not be used in this study because at no time were ANC results scheduled to be collected on 3 consecutive days. Thus, the lower-than-expected neutrophil engraftment in the current study was attributable to the higher single-day engraftment criteria.
The original sample size of the study was 200 subjects, but because of slow enrollment, the study was stopped after only 155 subjects were randomized. The decision to stop the study was made by the sponsor in consultation with a data-safety monitoring board. Stopping the study early enabled the release of the results sooner, while still allowing the objectives of this exploratory study to be fulfilled in providing an estimate of severe GVHD. As this was an estimation study, reducing the sample size would only affect the precision for the estimate of the primary end point. If the results had demonstrated superior efficacy to support the need for additional trials, stopping this study early would have enabled those trials to begin sooner, perhaps by as much as 1 year. Unfortunately, the study results showed a treatment difference of only 1% for the primary efficacy end point of grade 3 --4 acute GVHD (17% placebo vs 16% palifermin), which was well below any efficacy threshold to pursue further studies.
Clinical trials are often planned based on important findings in animal models of transplantation. However, human studies often do not confirm these findings, making extrapolation from animal models complex and challenging. Palifermin showed clinical benefit as a mucoprotective agent in autologous hematopoietic cell transplantation, 9 but the hope of palifermin as an agent to prevent GVHD without losing graft-vs-tumor effect in allo-SCT has not been realized in this study. Based on the findings of this exploratory study, no additional, larger study is planned to evaluate this dose of palifermin (three daily doses of 60 mg/kg before allo-SCT and a single, collapsed dose of 180 mg/kg after conditioning therapy but before allo-SCT) to reduce GVHD or oral mucositis in allo-SCT. 
